Prospective CoHoRt Of Non-infectious Intermediate, pOsterior or panuveitiS

Study Overview
=================
Brief Summary
-----------------
prospective, cohort, longitudinal, multicenter, non-randomized study of patients with non-infectious posterior segment uveitis or panuveitis, with a group of control patients (scheduled for cataract or vitreoretinal surgery) and constitution of biological collection.

Detailed Description
-----------------
Description of the clinical characteristics and evolution in a large cohort of patients with non-infectious uveitis, allowing to identify prognostic or predictive factors of response after treatment of these different forms of non-infectious uveitis of the posterior segment or panuveitis (factors that are currently not well known). Uveitis patients: Blood sample (20ml): Additional 20 ml blood sample during the first visit and potentially during follow-up (if necessary) for the purpose of the biological collection; Ocular sample (aqueous humor, vitreous): if required by the clinical context for the needs of the biological collection; Specific imaging: adaptive optics or Doppler holography, these procedures will be indicated on a case-by-case basis, at the investigator's discretion, and concern only patients with inflammatory vascular damage (5 to 10% of patients in the uveitis cohort); Quality of Life NEI-VFQ 25: provided at the inclusion visit and at follow-up visits M3-V2, M12-V5 and M24-V7. Control patients: Blood sample (20ml): Additional 20 ml blood sample during the inclusion visit at the time of the surgical scheduled procedure for the needs of the biological collection; Ocular sample (aqueous humor, vitreous): considered as surgical waste, the tissue residues will be collected during the scheduled surgical procedure for cataract or vitreoretinal surgery for the needs of the biological collection;

Official Title
-----------------
Prospective CoHoRt Of Non-infectious Intermediate, pOsterior or panuveitiS

Conditions
-----------------
Non-infectious Uveitis

Intervention / Treatment
-----------------
* Diagnostic Test: care strategy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: UVEITIS Patients: Adult patients (≥ 18 years); Non-infectious uveitis; Intermediate, posterior or panuveitis; Inflammatory activity requiring treatment with either one or more of the followings: Systemic corticosteroids or periocular or intravitreal injections of corticosteroids; Immunosuppressants: methotrexate, azathioprine, cyclosporine, etc.; Biotherapy: infliximab, adalimumab, tocilizumab; Patients with health insurance; Written Informed consent obtained at enrolment in the study. Control patients: Adult patients (≥ 18 years); Scheduled patients ( Non-urgente procedure) for cataract or vitreoretinal surgery; Patients with health insurance; Written Informed consent obtained at enrolment in the study. Exclusion Criteria: Uveitis Patients: Isolated anterior uveitis ; Inactive disease defined as: Absence of inflammatory chorioretinal and/or inflammatory retinal vascular lesion; Anterior chamber cell grade< 0.5+; Vitreous haze grade <0.5+; Pregnant or breastfeeding woman at the inclusion visit; Patient under legal protection ( curatelle  or  tutelle ); Patient denied freedom by a legal or administrative order. Control patients: Pregnant or breastfeeding woman; Unscheduled (urgent) cataract or vitreoretinal surgery; Patient under legal protection ( curatelle  or  tutelle ); Patient denied freedom by a legal or administrative order.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Uveitis Patients<br>Uveitis Patients: intermediate, posterior or panuveitis noninfectious uveitis with Inflammatory activity requiring treatment with either one or more of the following: Systemic corticosteroids or periocular or intravitreal injections of corticosteroids Immunosuppressants: methotrexate, azathioprine, ciclosporine…. Biotherapy: infliximab, adalimumab, tocilizumab | Diagnostic Test: care strategy<br>* Uveitis patients: Blood sample (20ml): Additional 20 ml blood sample during the first visit and potentially during follow-up (if necessary) for the purpose of the biological collection; Ocular sample (aqueous humor, vitreous): if required by the clinical context for the needs of the biological collection; Specific imaging: adaptive optics or Doppler holography, these procedures will be indicated on a case-by-case basis, at the investigator's discretion, and concern only patients with inflammatory vascular damage (5 to 10% of patients in the uveitis cohort); Quality of Life NEI-VFQ 25: provided at the inclusion visit and at follow-up visits M3-V2, M12-V5 and M24-V7.<br>|
| Active Comparator: Control Patients<br>scheduled for cataract or vitreoretinal surgery | Diagnostic Test: care strategy<br>* Uveitis patients: Blood sample (20ml): Additional 20 ml blood sample during the first visit and potentially during follow-up (if necessary) for the purpose of the biological collection; Ocular sample (aqueous humor, vitreous): if required by the clinical context for the needs of the biological collection; Specific imaging: adaptive optics or Doppler holography, these procedures will be indicated on a case-by-case basis, at the investigator's discretion, and concern only patients with inflammatory vascular damage (5 to 10% of patients in the uveitis cohort); Quality of Life NEI-VFQ 25: provided at the inclusion visit and at follow-up visits M3-V2, M12-V5 and M24-V7.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Imaging database development | To develop an imaging database of Non-Infectious Uveitis of the posterior segment (NIUPS) using multimodal imaging | 60 months | 
| Biological constitution | To Constitute a biological collection of ocular and blood samples of NIUPS patients and controls | 60 months | 
| medico economic costs estimation | To estimate the current costs of treatment by ensuring linkage of cohort patients to the national claims database | 60 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
non-infectious uveitis